Newest first
New topics page 16
Topics ordered by when they were created rather than by activity. This is where a question that nobody has answered yet is easiest to find — and answering one is the fastest route to a first solution badge.
1,535 topics · page 16 of 40
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
What consumer-accessible tests can and cannot determine
What consumer-accessible tests can and cannot determine — that is the question, and I have not found it answered plainly anywhere I have looked. Posting the method first, because I know what the first three…
|
2 | 17k | 1h | |
|
Micro-titration: a disputed topic, argued properly — one year on
Posting this under the heading it deserves: Micro-titration: a disputed topic, argued properly — one year on Everything below is what sits behind that. A question about technique rather than about dose. I…
|
+63 | 68 | 35k | 1d |
|
Completing a dose with a second syringe, and the dead-volume arithmetic
Posting this under the heading it deserves: Completing a dose with a second syringe, and the dead-volume arithmetic Everything below is what sits behind that. I have read the maintained page on this and I…
|
+65 | 76 | 7.4k | 1d |
|
About the Storage & stability category
Refrigeration, excursions, light exposure, freeze-thaw, beyond-use dating, and what published stability data actually covers. This post is a community wiki: any member at trust level 3 or above can edit it,…
|
4 | 57k | 4mo | |
|
The 2.5 mg starting dose is not a therapeutic dose — why that matters
The 2.5 mg starting dose is not a therapeutic dose — why that matters Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl J Med , 2016). Please…
|
+119 | 136 | 5.6k | 2mo |
|
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J…
|
2 | 1.9k | 5mo | |
|
Splitting an overlong document into two
Posting this under the heading it deserves: Splitting an overlong document into two Everything below is what sits behind that. Nominating something for promotion into the documentation commons. The topic in…
|
+30 | 34 | 6.2k | 1d |
|
[2026 update] Confounding by indication, explained with a concrete example
Confounding by indication, explained with a concrete example Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a…
|
+103 | 116 | 22k | 5mo |
|
Why catalogue breadth is not evidence of anything
Why catalogue breadth is not evidence of anything I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…
|
2 | 38k | 2d | |
|
A comparison of home results against a laboratory result on the same vial — does this still hold?
A comparison of home results against a laboratory result on the same vial — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Working through the…
|
+2 | 6 | 15k | 11h |
|
Rotating between abdomen, thigh and upper arm: absorption differences
On the subject in the title: Rotating between abdomen, thigh and upper arm: absorption differences Working notes rather than a conclusion. Reporting something rather than asking about it, in case the pattern…
|
2 | 3.5k | 5mo | |
|
Trifluoroacetate content and its consequences
Trifluoroacetate content and its consequences — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a certificate in front of me…
|
+123 | 134 | 31k | 5mo |
|
Five questions in one post gets you one answer — how to split them
On the subject in the title: Five questions in one post gets you one answer — how to split them Working notes rather than a conclusion. Question in the title. Context below, and I have tried to include the…
|
+84 | 90 | 1k | 2mo |
|
Second pass at: Pregnancy and pregnancy planning: contraindication and washout
Second pass at: Pregnancy and pregnancy planning: contraindication and washout Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a…
|
+111 | 127 | 1.6k | 6mo |
|
Bioimpedance and hydration: why the number moves
Bioimpedance and hydration: why the number moves — setting out what I have, and where I think it stops being reliable. Longitudinal report with the method stated, because a number without a method is not a…
|
+62 | 70 | 13k | 23d |
|
Reading a syringe in poor light, and how to avoid needing to — what changed since
Posting this under the heading it deserves: Reading a syringe in poor light, and how to avoid needing to — what changed since Everything below is what sits behind that. I have read the maintained page on this…
|
+3 | 7 | 27k | 27d |
|
Primary endpoint hierarchies and why order matters
Primary endpoint hierarchies and why order matters Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024) with SURPASS-2 ( N Engl J…
|
4 | 308 | 3mo | |
|
Follow-up: The retatrutide phase 2 obesity paper, read closely
The retatrutide phase 2 obesity paper, read closely — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think it…
|
+19 | 23 | 16k | 2d |
|
Coming back to: Reading a supplier's product description as a marketing document
Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…
|
+35 | 39 | 688 | 5mo |
|
Residual solvents and scavengers: what is looked for — what changed since
Residual solvents and scavengers: what is looked for — what changed since — setting out what I have, and where I think it stops being reliable. Posting the method first, because I know what the first three…
|
+37 | 41 | 7k | 2mo |
|
Charge states for a 4 kDa peptide, worked through — the long version
Charge states for a 4 kDa peptide, worked through — the long version Writing it up because I had to work it out twice and would rather nobody else did. Working through the identity arithmetic and I would like…
|
2 | 293 | 3mo | |
|
Stability of BPC-157 in solution: what has been measured — one year on
On the subject in the title: Stability of BPC-157 in solution: what has been measured — one year on Working notes rather than a conclusion. Comparing STEP 2 ( Lancet , 2021) with STEP 1 ( N Engl J Med , 2021)…
|
+84 | 98 | 7.8k | 18h |
|
Anaesthesia and elective surgery: the aspiration question
Posting this under the heading it deserves: Anaesthesia and elective surgery: the aspiration question Everything below is what sits behind that. A question about technique rather than about dose. I have been…
|
+103 | 115 | 6.6k | 3mo |
|
Distinguishing a red flag from an inconvenience
Distinguishing a red flag from an inconvenience — setting out what I have, and where I think it stops being reliable. I would like to talk about documentation quality as a signal, separately from product…
|
2 | 38k | 6mo | |
|
Blinding yourself: practical methods and their limits
On the subject in the title: Blinding yourself: practical methods and their limits Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with STEP 4 ( JAMA , 2021) and finding the…
|
+40 | 44 | 33k | 5d |
|
Follow-up: Lyophilisation and why the cake looks the way it does
Lyophilisation and why the cake looks the way it does Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what this number means before I repeat it…
|
+10 | 14 | 11k | 3mo |
|
Reporting a good result: why nobody bothers and why they should
Reporting a good result: why nobody bothers and why they should — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the…
|
2 | 3.5k | 17h | |
|
Comparing my trajectory with the trial curves, carefully — a second dataset
Comparing my trajectory with the trial curves, carefully — a second dataset — setting out what I have, and where I think it stops being reliable. Maintenance rather than loss, which is the part of this that…
|
+77 | 81 | 16k | 11h |
|
[2026 update] Area percent versus weight percent: the confusion that causes most arguments
On the subject in the title: Area percent versus weight percent: the confusion that causes most arguments Working notes rather than a conclusion. Posting the method first, because I know what the first three…
|
+65 | 70 | 1.1k | 16d |
|
Manufacturer assistance programmes and their eligibility rules
On the subject in the title: Manufacturer assistance programmes and their eligibility rules Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category…
|
+37 | 42 | 32k | 11d |